Tolterodine

Generic Name: Tolterodine

Brand Names: Detrol, Detrusitol

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₁NO

CAS Number: 124937-51-5

Unique Ingredient Identifier: WHE7A56U7K

Background: Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

Indication: For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).

Associated Conditions: Urinary Urge Incontinence

Clinical Trials

Treatment of Incontinence Without Memory Problems

Phase 4

Completed

Conditions: Urinary Incontinence, Urge
Urge Incontinence

Interventions: Drug: Mirabegron
Drug: Tolterodine Tartrate

First Posted Date: 2015-05-07

Last Posted Date: 2019-04-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 23

Registration Number: NCT02436889

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Phase 4

Completed

Conditions: Overactive Bladder (OAB)

Interventions: Drug: Mirabegron tablet
Drug: Imidafenacin tablet
Drug: Tolterodine capsule
Drug: Solifenacin tablet
Drug: Propiverine tablet

First Posted Date: 2014-11-19

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 649

Registration Number: NCT02294396

Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II

Phase 4

Completed

Conditions: Chronic Pain

Interventions: Drug: Amitriptyline
Drug: Tolterodine

First Posted Date: 2014-10-06

Last Posted Date: 2019-01-24

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 48

Registration Number: NCT02256956

Locations: 🇨🇭
Dep. of Anesthesiology, Bern University Hospital, Bern, Switzerland

Genetic Determinants of Amitriptyline Efficiency for Pain Treatment

Phase 4

Completed

Conditions: Chronic Pain

Interventions: Drug: Amitriptyline
Drug: Tolterodine

First Posted Date: 2014-10-06

Last Posted Date: 2019-01-24

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 48

Registration Number: NCT02256943

Locations: 🇨🇭
Dep. of Anesthesiology, Bern University Hospital, Bern, Switzerland

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

Phase 4

Completed

Conditions: Overactive Bladder (OAB)

Interventions: Drug: Tolterodine ER
Drug: Mirabegron

First Posted Date: 2014-05-15

Last Posted Date: 2020-02-26

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 376

Registration Number: NCT02138747

Locations: 🇺🇸
Site US10010 Skyline Urology, Sherman Oaks, California, United States
🇨🇦
Site CA15003 The Male/Female Health & Research Centre, Barrie, Ontario, Canada
🇺🇸
Site US10035 Millennium Clinical Research Center, Arlington, Virginia, United States

and more 27 locations

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine

Phase 4

Completed

Conditions: Healthy
Pharmacokinetics of Mirabegron and Tolterodine

Interventions: Drug: tolterodine
Drug: mirabegron

First Posted Date: 2013-10-17

Last Posted Date: 2013-10-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT01964183

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: Detrusitol 4mg QD and Oxybutynin ER 5mg QD
Drug: Detrusitol 4mg QD

First Posted Date: 2013-04-04

Last Posted Date: 2017-03-08

Lead Sponsor: Buddhist Tzu Chi General Hospital

Target Recruit Count: 129

Registration Number: NCT01824420

Locations: 🇨🇳
Buddhist Tzu Chi General Hospital, Hualien, Taiwan

Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction

Phase 4

Completed

Conditions: Ureteral Obstruction

Interventions: Drug: Tamsulosin
Drug: Tolterodine ER

First Posted Date: 2012-12-05

Last Posted Date: 2019-07-10

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 181

Registration Number: NCT01741454

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

Phase 2

Completed

Conditions: Overactive Bladder

Interventions: Drug: Tolterodine tartrate extended release capsules
Drug: Desmopressin orally disintegrating tablets
Drug: Placebo orally disintegrating tablets

First Posted Date: 2012-11-20

Last Posted Date: 2018-09-12

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 106

Registration Number: NCT01729819

Locations: 🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸
Moez Khorsandi, DO, Los Angeles, California, United States
🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States

and more 21 locations

Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1

Phase 4

Completed

Conditions: Bladder Outlet Obstruction

Interventions: Drug: Detrusitol 4 mg QD
Drug: Doxazosin 4 mg QD

First Posted Date: 2012-08-09

Last Posted Date: 2014-06-25

Lead Sponsor: Buddhist Tzu Chi General Hospital

Target Recruit Count: 395

Registration Number: NCT01661621

Locations: 🇨🇳
Buddhist Tzu Chi General Hospital, Hualien, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy